Clinical Trial Update: Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children [Phase 4]

View source ↗

Summary

Phase 4 study of a new formulation of the DTPa-HBV-IPV/Hib vaccine as a booster in children aged 18-23 months; results were posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acellular Pertussis
• Diphtheria
• Hepatitis B
• Poliomyelitis
• Tetanus

Drugs mentioned

• DTPa-HBV-IPV/Hib vaccine (new formulation) (DTPa-HBV-IPV/Hib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Poliomyelitis, Acellular Pertussis | Phase 4 | Status: COMPLETED | Results posted: 2009-08-10